COLINZ LABORATORIES LTD.

Colinz Laboratories Ltd announced its 40th Annual General Meeting (AGM) scheduled for Tuesday, September 22, 2026, at 2:30 PM IST. The meeting will be conducted via Video Conferencing or Other Audio Video Means (OAVM). Key agenda items include the adoption of the audited financial statements for the fiscal year ended March 31, 2026, and the reports of the Directors and Independent Auditors. Additionally, the AGM will address the re-appointment of Mr. N. K. Menon as a Director retiring by rotation and the appointment of Mrs. Vijaya Mani as an Additional Director (Non-Executive, Non-Independent) effective November 11, 2025. The company also reminded shareholders to convert physical shares to demat mode.

Colinz Laboratories Ltd has announced the schedule for its 40th Annual General Meeting (AGM) to be held on September 22, 2026, via Video Conferencing/Other Audio Visual Means. The company has also informed about the book closure period from September 15, 2026, to September 22, 2026, inclusive, for the purpose of the AGM. A cut-off date of September 15, 2026, has been set for determining shareholders eligible for e-voting. The remote e-voting facility will be available from September 19, 2026, to September 21, 2026.

Colinz Laboratories Limited has issued the notice for its 40th Annual General Meeting (AGM), scheduled for Tuesday, September 22, 2026, at 2:30 PM IST. The meeting will be conducted via Video Conferencing or Other Audio Video Means (OAVM). Key agenda items include the adoption of audited financial statements for the fiscal year ended March 31, 2026, the re-appointment of Mr. N. K. Menon as a Director, and the appointment of Mrs. Vijaya Mani as a Director. Additionally, the AGM will address the re-appointment of Mr. N. K. Menon as Whole Time Director & Chief Executive Officer and discuss his remuneration.

Saffron Capital Advisors Pvt Ltd, acting as the Manager to the Open Offer, has submitted a Letter of Offer to BSE for the public shareholders of Colinz Laboratories Ltd. The offer is made by Acquirer 1 (Annjana Dugar), Acquirer 2 (Likhitta Dugar), Acquirer 3 (Antariksh Dugar), and Padam Dugar (Person Acting In Concert). They aim to acquire up to 6,54,966 equity shares, representing 26% of the voting share capital, at a price of ₹54 per share. The total value of the open offer is ₹3,53,68,164. This open offer is being made pursuant to SEBI (SAST) Regulations, 2011, for substantial acquisition of shares and voting rights accompanied by a change in control. The offer is not conditional on minimum acceptance.

Colinz Laboratories Ltd held a Board of Directors meeting on July 30, 2026, where they approved the Un-Audited Financial Results for the quarter ended June 30, 2026, along with the Statutory Auditors' Limited Review Report. The board also approved the Director's Report, Management Discussion Report, Corporate Governance Report, and related certifications for the year ended March 31, 2026. Key appointments were made, including Mrs. Vijaya Mani as Director and Mr. N. K. Menon as Whole-time Director and CEO for an extended term. The 40th Annual General Meeting is scheduled for September 22, 2026, with the Register of Members closing from September 1 to September 22, 2026. The company also appointed M/s. Sanjay Dholakia & Associates as Secretarial Auditor and CA Ajay Ramsevak Sharma as Internal Auditor for FY 2026-27.

Colinz Laboratories Ltd's Board of Directors convened on July 31, 2026, to approve the Un-Audited Financial Results for the quarter ended June 30, 2026. The results underwent a limited review by the statutory auditors. The Board also approved the Directors' Report, Management Discussion Report, Corporate Governance Report, and CEO's certification for the year ended March 31, 2026. Additionally, the appointment of Mrs. Vijaya Mani as a Director and Mr. N. K. Menon as Whole-time Director and CEO for a further term were approved, subject to member approval. The date for the 40th Annual General Meeting was finalized for September 22, 2026, with the Register of Members closing from September 15 to September 22, 2026. The company also appointed CA Ajay Ramsevak Sharma as Internal Auditor and M/s. Sanjay Dholakia & Associates as Secretarial Auditor for FY 2026-27.

Colinz Laboratories Ltd has announced a Board of Directors meeting scheduled for July 30, 2026. The meeting will inter alia consider and approve the Un-Audited Financial Results for the quarter ended June 30, 2026. Additionally, the board will discuss and approve the Director's Report, Management Discussion, Corporate Governance Report, CEO's Certification, and other related documents for the financial year ended March 31, 2026. The meeting will also take note of the Secretarial Audit Report for FY26, fix dates for Book Closure and Record Date, and recommend the appointment of the Secretarial Auditor and Internal Auditor for FY27. A draft notice for the forthcoming Annual General Meeting will also be approved. The trading window closure for designated persons will end on the second trading day after the board meeting.

Colinz Laboratories Ltd has announced the closure of its trading window for designated persons from July 1, 2026, until 48 hours after the announcement of its financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code for preventing insider trading. The specific date for the Board Meeting to declare these financial results will be communicated in due course. The company has provided its BSE code (531210) and contact details for acknowledgment.

Saffron Capital Advisors Pvt Ltd, acting as the Manager to the Open Offer, has submitted a Draft Letter of Offer (DLOF) to BSE. The open offer is being made by Antariksh Dugar (Acquirer 3), along with Annjana Dugar (Acquirer 1), Likhitta Dugar (Acquirer 2), and Padam Dugar (PAC), to acquire up to 6,54,966 equity shares of Colinz Laboratories Ltd. This represents 26% of the voting share capital. The offer price is ₹54 per equity share, valuing the total acquisition at ₹3,53,68,164. The offer is being made pursuant to SEBI (SAST) Regulations, 2011, for substantial acquisition of shares and voting rights accompanied by a change in control, and is not conditional on minimum acceptance.

Colinz Laboratories Limited has informed the exchange that Regulation 32 of SEBI (LODR) Regulations, 2015, pertaining to the statement of deviation or variation for proceeds of public issue, rights issue, preferential issue, or QIP, is not applicable to the company for the quarter ended June 30, 2026. This is because the company has not undertaken any such fundraising activities during the period. The disclosure is made as per regulatory requirements.